Abstract:
Abstract #800056
aperr
savage
2
8
2003-11-14T16:00:00Z
2003-11-14T16:00:00Z
1
223
1273
Computer Services
10
2
1563
9.3821
6 pt
2
2
Purpose: Compare deposition of doxorubicin in the periphery
of thermal lesions in swine liver using free doxorubicin or a heat-sensitive
liposomal vector containing doxorubicin as an adjuvant therapy to
radiofrequency ablation (FRA).
Materials and Methods: Three pigs underwent RFA of the liver
during intravenous administration of a low-temperature sensitive formulation of
liposomal doxorubicin that deploys its contents at predominantly 39 to 42C. Two
pigs were treated with identical RFA with intravenous free doxorubicin without
liposome. Doxorubucin dosing was 0.7mg/kg body weight. Two pigs underwent
ablation without drug, serving as controls. Liver tissue specimens collected at
regular intervals from the thermal ablation center were analyzed for
doxorubicin and its metabolites (aglycone and doxorubicinol)). Thermal maps and
corresponding drug levels were analyzed and the area under the time temperature
curve for specific distances was correlated.
Results: Between 2 to 4 times as much doxorubicin was
deposited in and around the thermal lesions with the low temperature sensitive
formulation of liposomal doxorubicin compared with free doxorubicin.
Conclusion: Liposome-encapsulated doxorubicin (with special
low temperature deployment chemistry) may be deposited at the periphery of
thermal lesions in the swine model. This combination treatment may prove more
effective as a therapy for focal liver tumor than either treatment alone. (M.A. is a paid consultant for Celsion, Inc;
Celsion Inc. provided the liposomal carrier.)
Pritchard MD, PhD, W,
Hot Topic: Heat-Sensitive Liposomes as Carriers for Doxorubicin Increase Local Drug Deposition during Radiofrequency Ablation. Radiological Society of North America 2003 Scientific Assembly and Annual Meeting, November 30 - December 5, 2003 ,Chicago IL.
http://archive.rsna.org/2003/3800056.html
